$135M Funding to Accelerate Global Expansion of Installed Base and Deliver New Solutions at the Convergence of Single-Cell Biology and Proteomics
Recently, IsoPlexis announced a $135 million Series D financing round led by Perceptive Advisors with participation from other new investors. This funding will help us accelerate expanding our gold-standard functional proteomics platform globally, delivering solutions at the convergence of single-cell biology and proteomics to every lab. We plan to use the proceeds from this financing to grow our R&D teams to meet increasing demand and accelerate our next generation single-cell biology product development roadmap.
Identifying Adaptive Phosphoproteomic Signaling Networks with IsoPlexis’ Intracellular Signaling Omics
Our intracellular signaling omics application, specifically our Single-Cell Intracellular Proteome solution, analyzes phosphoprotein signaling cascades across up to 1500 single cells per chip, identifying and resolving adaptive resistance pathways to combat therapeutic resistance. In December, we were honored to have the Single-Cell Intracellular Proteome solution named a Top 10 Innovation of 2020 by The Scientist. Each year, The Scientist features ten of the latest tools, technologies, and techniques with the most significant impact on the healthcare and life sciences industries. Our unique intracellular proteome solution was chosen from among dozens of submissions by a panel of expert, independent judges for its potential to foster rapid advances, accelerate research, and facilitate biological discovery.
In a 2016 paper published in Cancer Cell, researchers were able to identify a solution to overcome resistant cells by analyzing the differential responses in signaling coordination. They showed that drug resistance could take place via an adaptive, non-genetic mechanism that is initiated just days after drug administration. IsoPlexis’ award-winning Single-Cell Intracellular Proteome solution facilitated these critical insights, uniquely measuring cellular communication via phosphorylation events and adaptive resistance pathways on the fully automated IsoLight system.
With this technology in hand, researchers studying malignant tumors can obtain a full functional understanding of the signaling pathways and protein interactions associated with tumor growth, metastasis, therapeutic resistance, or clinical improvement, and identify potential therapies tailored to the patient.
Sample to Insights for Any Lab with IsoPlexis’ Walk-Away High-Plex Proteomics
Two additions in 2020 allowed us to expand our walk-away proteomics to virtually every lab worldwide: CodePlex and the IsoSpark. These products are revolutionizing functional proteomics and precision medicine. The benchtop IsoSpark system has all the fully automated advanced fluidics and precision imaging provided by the high-throughput IsoLight, with a reduced 18-inch footprint and 4-chip capacity. The IsoSpark is scalable to fit any lab’s needs, with the IsoSpark Duo enabling complete functional immune landscaping with the ability to analyze multiple different cell types across 8 chips simultaneously.
Our revolutionary CodePlex chip is the first fully automated solution for running highly multiplexed bulk cytokine assays. This chip requires only five minutes of hands-on sample loading as the IsoLight or IsoSpark does the rest—no need for separate instruments as our system is designed to run both single-cell and bulk proteomic analyses. Users simply load the chips and walk-away, no extensive training or specialized personnel needed. Researchers come back later that same day to fully analyzed, publication-ready data at the touch of a button with our integrated IsoSpeak software.
IsoPlexis’ Single-Cell Immune Profiling and Blood-Based Biomarker Predicts Progression-Free Survival in Combination Checkpoint Therapy, Presented by Collaborators from Nektar Therapeutics
At the SITC Conference in November of 2020, Nektar Therapeutics announced some exciting new data from a clinical trial they in collaboration with IsoPlexis. Our platform found that the week one Polyfunctional Strength Difference of CD8+ T cells from the blood was a highly predictive biomarker of progression-free survival of metastatic melanoma patients treated with the Nivo/Bempeg (NKTR-214) combination therapy. IsoPlexis’ functional immune landscaping predicted the progression-free survival at week one, when patient response typically isn’t able to be evaluated until weeks later with traditional technologies. With this blood-based biomarker, IsoPlexis accelerates insights into the path toward overcoming difficult-to-treat cancers such as metastatic melanomas, identifying treatments associated with a durable response in patients.
As we surpass 100 systems in the field and continue to grow at a rapid rate, we are excited to see what the coming year brings to the landscape of precision curative medicine and proteomic immune discovery. With applications in cancer immunology, cellular and regenerative medicine, COVID-19, inflammation and neurology, and more, IsoPlexis is revealing new layers of biological data, allowing researchers to quickly obtain crucial data that strongly correlate with in vivo biology and patient outcomes.
We look forward to launching more exciting new products in 2021! Get in touch to find out how we can advance your programs.